69results about "Blood disorder" patented technology

The present invention generally relates to the improvement of tissue health by increasing local blood flow. In some aspects of the invention, increased local blood flow is effected by the transdermal delivery of the nitric oxide precursor L-arginine and/or its derivatives alone, or optionally in conjunction with an adjunct such as theophylline. The transdermal delivery is effected, in certain embodiments through the means of a hostile biophysical environment, such as that created by a high ionic strength environment. Various pathological states caused by, or occurring in conjunction with, insufficient blood flow, can be treated using the systems and methods of the invention as described herein. In other embodiments, increased blood flow using the systems and methods of the invention may result in enhanced healing, for example, through greater availability of the constituents of the blood. Examples of conditions which may benefit from increased blood flow include, but are not limited to, erectile dysfunction, hair loss, female sexual dissatisfaction, sagging facial or other body tissue, peripheral vascular disease including claudication, neuropathy, skin ulcers, bone healing, wound healing, viral and bacterial infection, and skin grafting.

The invention relates to a method of treatment of resistance to platelet inhibitors, i.e. a method to overcome resistance of treatment with platelet inhibitors, said method comprising administering a therapeutically effective amount of dipyridamole in combination with a platelet inhibitor and, optionally, in combination with a third antithrombotic component such as direct thrombin inhibitors, factor Xa inhibitors, combined thrombin/factor Xa inhibitors, heparin, low molecular weight heparin, argatroban, bivalrudin, hirulog or polyglycans to a patient in need thereof. The invention further relates to the use of dipyridamole for the manufacture of a pharmaceutical composition for treatment of resistance to platelet inhibitors. The invention also relates to a method to diagnose resistance to treatment with platelet inhibitors, said method comprising measurement of the density of binding of Annexin V on platelets.

Described herein are methods of inhibiting M-CSF activity, and, in particular, M-CSF/c-fms dependent cell signaling. In a first embodiment of the invention, one administers to a mammal viral vectors that deliver genes experessing antisense c-fms RNA; in a second embodiment, one induces in vivo production of a high-affinity soluble c-fms protein that competes for non-bound M-CSF; in a third embodiment, one administers a ribozyme-viral vector against c-fms mRNA; and in a fourth embodiment, one administers oligodeoxynucleotides that inhibit expression of c-fms gene product. The methods may be used to treat any disease in which M-CSF activity plays a role, and are particularly effective in treating and preventing atherosclerosis.

Embodiments of the present invention are directed primarily, but not exclusively, to a method for treating and preventing cardiovascular disease by inhibiting receptors to M-CSF. Other embodiments of the present invention include any and all biologic and/or pathobiologic phenomena mediated in whole or in part by M-CSF signaling through its receptor. Pathobiologic phenomena include, but are not limited to, disease entities such as osteoporosis, Alzheimer's disease, diabetes mellitus (Type 1 and/or Type 2), infectious diseases, cancer, and inherited disorders characterized by defects in one or more components in the M-CSF signaling pathway.

A process is provided for preparing spiro-hydantoin compounds of the formula II

wherein Z is N or CR_4b; K and L are independently O or S; Ar is an optionally substituted aryl or heteroaryl; A₂ is a linker, G′ is a linker; Q is a linker; and R₂, R_4a, R_4c, and R_h are defined in the specification. The process optionally includes the enantiomeric separation of intermediates to allow preparation of enantiomers of the spiro-hydantoin compounds of formula II. Substituted spiro-hydantoin compounds may be prepared from the spiro-hydantoin compounds of formula II. The spiro-hydantoin compound of formula II and the substituted spiro-hydantoin compounds are useful in the treatment of immune or inflammatory diseases. Also, provided are products made by the instant inventive process and crystalline forms (prepared by any process) of the substituted spiro-hydantoin compound, 5-[(5S, 9R)-9-(4-Cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]non-7-ylmethyl]-thiophene-3-carboxylic acid, including solvates and salts thereof, as well as methods of use thereof. Crystalline forms of certain intermediates are provided.

The invention is directed to transcription activator-like effector nuclease (TALEN)-mediated DNA editing of disease-causing mutations in the context of the human genome and human cells to treat patients with compromised genetic disorders.

The present invention relates to a method for processing human placental cell sample, a human placental cell sample obtained according to said method for processing human placental cell sample, a human placental cell bank, a method for banking human placental cells, a method for searching human placental cell sample in said human placental cell bank according to the present invention, a method for preparing human cord blood serum, use of human placental cells obtained by said method for processing human placental cell sample or human placental cell bank established by said method for banking human placental cells in treating human dysfunction and diseases due to cell injury or cell malfunction, as well as a method for treating human dysfunction and diseases due to cell injury or cell malfunction.

The present invention refers to the use of phthalimide and/or sulphonamide derivatives with nitric oxide donor properties, which have important activities in increasing the gamma-globin gene expression and anti-inflammatory and analgesic activities, effective in the treatment of hematologic diseases which require reducing the TNF-α levels and an exogenous source of nitric oxide. More particularly, the present invention describes the use of such phthalimide and/or sulphonamide derivatives for the treatment of sickle-cell disease. The invention also has as a novel characteristic the disclosure of new functionalized phthalimide derivatives designed from the prototypes thalidomide and hydroxyurea, and designed rationally through the strategy of molecular hybridization for the treatment of said diseases. The invention still discloses a new method for obtaining a specific sulphonamide derivative which can be used in the preparation of a drug for the treatment of diseases which require reducing the levels of the TNF-α factor and an exogenous source of nitric oxide.

The present invention provides a traditional Chinese medicine health care product, its preparation method and its application. The traditional Chinese medicine health care product is prepared by taking Cordyceps cicadae from artificial cultivation as a main raw material. The traditional Chinese medicine health care product has the functions of improving anemia and sleep disorders. Animal experiments show that the traditional Chinese medicine health care product has the advantages of safety, effectiveness and no obvious side effect.

Fibrin-binding peptides having high binding affinity and excellent physical characteristics compared to previously known fibrin-binding peptides are provided. These fibrin-binding peptides may be conjugated to a detectable label or a therapeutic agent and used to detect and facilitate treatment of pathological conditions associated with the presence of fibrin such as thrombic, angiogenic and neoplastic conditions. These peptides may be used in imaging processes such as MRI, ultrasound and nuclear medicine imaging (e.g. PET, scintigraphic imaging., etc.). The peptides may also be used therapeutically. The present invention also provides processes and methods for making and using such peptides and conjugates thereof.

The present invention is to provide an imidazolidinedione derivative and oxazolidinedione derivative represented by the following general Formula (I) having the chymase and/or tryptase inhibition activity [wherein R<1 >and R<2 >are the same or different, and denote a lower alkyl group or a phenyl group, or R<1 >and R<2 >are taken together to form a ring, R<3 >denotes an optionally substituted naphthyl group or heterocyclic group, A denotes oxygen or NR<4 >(R<4 >is hydrogen or optionally substituted lower alkyl group), or NB<2>R<5 >(R<5 >is aryl group, and B<2 >is carbonyl group or sulfonyl group), and B<1 >denotes a carbonyl group or a sulfonyl group], or a pharmaceutically acceptable salt thereof.

A method for inhibiting dipeptidyl-peptidase IV is provided and includes administering a peptide to the dipeptidyl-peptidase IV, in which the peptide is isolated from a gelatin hydrolysate produced by enzymatic digestion with alcalase (ALA), bromelain (BRO), and flavourzyme (FLA).

The presently disclosed subject matter relates generally to the fields of molecular biology and medicine. More particularly, it concerns methods involving the use of GSK3 inhibitors in combination with radiation therapies. In some embodiments, administration of a GSK3 inhibitor to a subject results in an amelioration of cognitive decline, toxicity to vascular endothelial cells, and/or neuron death associated with radiation therapy alone.

The invention discloses a nutrition wine for nourishing yin and invigorating the kidney. The nutrition wine is prepared by pretreating the raw materials of 10-30 parts of Chinese yam, 20-40 parts of chrysanthemum, 5-15 parts of cinnamon, 10-20 parts of rhizoma polygonati, 8-12 parts of oyster, 20-30 parts of mulberry, 5-15 parts of white granulated sugar, 5-10 parts of caulis spatholobi and 900-1,000 parts of 42-degree distillate spirit; mixing and dipping; adjusting sugar; settling; and filtering. The nutrition wine has the functions of nourishing yin and yang, activating and enriching blood and building and invigorating body, can recuperate the subhealth and common symptoms of a human body, balance bodily functions and improve immunity and can be taken for a long time and has no side effect on the human body.

Compositions include vitamin C, water and a reducing sugar, result in increased stability of vitamin C. Further the addition of alcohol to aqueous vitamin C compositions increased the stability of vitamin C. Moreover, aqueous vitamin C compositions having surfactant included therein enhance the absorption of vitamin C into skin. Methods of using the stable vitamin C compositions are also described.

A method for storing and using platelets and an associated platelet structure. At least one modified platelet is formed. Each modified platelet includes a platelet and at least one polymerated chemical. Each polymerated chemical includes a polymer covalently bonded directly to the platelet or includes the polymer and a linker molecule such that the linker molecule is covalently bonded to the platelet and the polymer is covalently attached to the linker molecule. The polymer of each polymerated chemical of each modified platelet is polyethylene glycol (PEG) or a PEG derivative. Forming each modified platelet does not include modifying the platelet membrane of each platelet with a glycan-modifying agent. The at least one modified platelet is stored in a temperature range below 20° C. for at least one hour. After being stored, the at least one modified platelet may be introduced into a mammal.

A plant originated alcohol soluble protein matrix and its preparation process are disclosed, belonging to the biological medical technology field. The plant originated alcohol soluble protein matrix is prepared by alcohol soluble protein micro sphere or heparin containing alcohol soluble micro sphere. Said plant originated alcohol soluble protein can be any of alcohol soluble protein of wheat, barley, rye, oat or corn. Said alcohol adopts C1-4 fatty alcohol. The preparation process of the plant originated alcohol soluble protein matrix adopts phase separation technology and dissolvent volatilizing technology

The invention discloses a preparation method of high-purity gynostemma pentaphylla total saponin for veterinary drugs. The preparation method is characterized in that a medicinal gynostemma pentaphylla total saponin medicinal material is used as a raw material, and the high-purity target product, namely the gynostemma pentaphylla total saponin for the veterinary drug, is obtained by high-efficiency extraction and separation on the basis of combination of technologies such as continuous countercurrent supersonic wave extraction, ceramic membrane microfiltration and macroporous resin adsorption separation with a conventional solvent reflux extraction principle. The preparation method has the advantages that the product purity and the product yield are improved, the product quality and the high quality are stabilized, the production cost is reduced, the requirements on the development of the high-purity gynostemma pentaphylla total saponin for the veterinary drugs and highly-processed products of gynostemma pentaphylla total saponin are satisfied, the production process is in line with environmental protection requirements, and the difficulty in the coordination of working procedures such as extraction, solvent recovery, enrichment and purification occurring in the volume production process of the gynostemma pentaphylla total saponin for the veterinary drugs is solved through the continuous improvement of the technology and the adjustment of technological processes and technical parameters.

The invention discloses a traditional Chinese medicine for treating anemia. The traditional Chinese medicine comprises the following components in part by weight: 50 to 100 parts of barbary wolfberry fruit, 50 to 100 parts of Chinese date, 50 to 100 parts of virgate wormwood herb, 50 to 100 parts of honeysuckles, 50 to 100 parts of donkey-hide glue, 50 to 100 parts of black sesame, 50 to 100 parts of longan, 40 to 80 parts of Chinese lobelia herb, 40 to 80 parts of astragals, 40 to 80 parts of scrophularia root, 40 to 80 parts of hairyvein agrimonia herb and bud, 40 to 80 parts of isatis indigotica fort, 40 to 80 parts of rehmanniae praeparatum, 40 to 80 parts of dwarf lilyturf tuber, 40 to 80 parts of weeping forsythiae capsule, 45 to 85 parts of houttuynia, 45 to 85 parts of gardenia, 5 to 85 parts of Indian buead,45 to 85 parts of golden thread and proper amount of honey and dextrine. The components of the traditional Chinese medicine for treating anemia are prepared into the medicament by processes of crushing, extracting, mixing, pelleting and the like. The formula of the traditional Chinese medicine has very good treatment effect on people with anemia and qi-blood deficiency and also has relatively good adjuvant treatment effect on patients with leukemia.

The present invention provides glucopyranosyloxypyrazole derivatives represented by the general formula:

wherein one of Q and T represents a group represented by the general formula:

while the other represents a lower alkyl group or a halo(lower alkyl) group; R¹ represents a hydrogen atom, an optionally substituted lower alkyl group, a lower alkenyl group, a cyclic lower alkyl group, etc.; R² represents a hydrogen atom, an optionally substituted lower alkyl group, a lower alkoxy group, a lower alkenyl group, a cyclic lower alkyl group, a cyclic lower alkoxy group, etc., which exert an excellent inhibitory activity in human SGLT2, and therefore are useful as drugs for the prevention or treatment of a disease associated with hyperglycemia such as diabetes, diabetic complications or obesity, pharmaceutically acceptable salts thereof or prodrugs thereof, production intermediates thereof and pharmaceutical uses thereof.

Disclosed is a composition for reprogramming somatic cells to generate embryonic stem cell-like cells, comprising: a) a Bmi1 (B cell-specific Moloney murine leukemia virus integration site 1) protein or a nucleic acid molecule coding for Bmi1; and b) an Oct4 protein or a nucleic acid molecule coding for Oct4. Also, a method is provided for reprogramming somatic cells to generate embryonic stem cell-like cells using the composition. In addition to reducing the number of the genetic factors conventionally needed, the composition and method allow the generation of pluripotent embryonic stem cell-like cells which have high potential in the cell therapy of various diseases.

The invention belongs to the field of wine brewing, in particular relates to a brewing method, and more particularly relates to a brewing method of agaricus bisporus and chenopodium quinata wine. According to the brewing method, agaricus bisporus and chenopodium quinata are used as raw materials, novel wine is prepared through fermentation, and the efficacies of reducing blood glucose, lowering blood pressure, reducing blood fat, resisting oxidation, resisting cancer, improving body immunity, relieving cough and reducing sputum, inducing diuresis and relaxing the bowels, expelling toxins and losing weight, and the like are enhanced; due to the adoption of the extrusion puffing method for pretreating chenopodium quinate, the utilization rate of chenopodium quinata is increased, and the costis reduced; the agaricus bisporus and chenopodium quinata wine contains rich nutritional ingredients including amino acids, unsaturated fatty acids, vitamins, minerals and polysaccharides, is convenient to use, is pure and soft in taste, is suitable for wide consumers, and has the broad market and development prospects.

The invention discloses cassia twig and poria cocos pills and a preparation method thereof. The cassia twig and poria cocos pills are prepared from, by weight, 190-210 parts of cassia twigs, 190-210 parts of poria cocos, 190-210 parts of cortex moutan, 190-210 parts of radix paeoniae rubra and 190-210 parts of peach kernels. The cassia twig and poria cocos pills have the effects of promoting blood circulation to remove blood stasis and relieving and eliminating lumps and can be used for treating symptoms of blood stasis retention in uterus, gestation threatened abortion, endless metrostaxis, uterine fibroid, endometriosis, ovarian cyst, annexitis and chronic pelvic inflammation; meanwhile, the cassia twig and poria cocos pills have the advantages of being reasonable in cost, small in toxic and side effects, convenient to take and short in curative effect; the cassia twig and poria cocos pills can be produced in a batched mode, are wide in appropriate people and have extremely high popularization value.